T. Rowe Price Investment Management, Inc. Verve Therapeutics, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $151 Billion
- Q1 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 2,491,949 shares of VERV stock, worth $10.8 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,491,949
Previous 2,352,599
5.92%
Holding current value
$10.8 Million
Previous $13.3 Million
14.17%
% of portfolio
0.01%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding VERV
# of Institutions
203Shares Held
79.4MCall Options Held
204KPut Options Held
101K-
Alphabet Inc. Mountain View, CA12.3MShares$53.3 Million5.03% of portfolio
-
Bvf Inc San Francisco, CA6.9MShares$29.8 Million1.39% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$28.6 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4MShares$17.3 Million2.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.96MShares$17.1 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $259M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...